✦ LIBER ✦

Fatal hyperlipaemia in a case of metastatic breast cancer treated by tamoxifen

✍ Scribed by Dr M. Noguchi; T. Taniya; K. Tajiri; K. Miwa; I. Miyazaki; H. Koshino; H. Mabuchi; A. Nonomura

Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 217 KB
Volume: 74
Category: Article
ISSN: 0007-1323
DOI: 10.1002/bjs.1800740714

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of aminoglutethimide

A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

✍ A. Lipton; H. A. Harvey; R. J. Santen; A. Boucher; D. White; A. Bernath; R. Dixo 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

Treatment of metastatic breast cancer in

Treatment of metastatic breast cancer in estrogen receptor positive patients a randomized trial comparing tamoxifen alone versus tamoxifen plus CMF

✍ W. R. Bezwoda; D. Derman; N. G. De Moor; M. Lange; J. Levin 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB 👁 2 views

Induction of apoptosis by tamoxifen and

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

✍ Paul A. Ellis; Gloria Saccani-Jotti; Robert Clarke; Stephen R.D. Johnston; Eliza 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 151 KB 👁 1 views

Hormonal breast cancer therapies have traditionally been considered cytostatic, but recent pre-clinical data suggest that anti-oestrogens can induce apoptosis. The aim of this study was to assess whether tamoxifen (TAM) and ICI 182780 (ICI) could induce apoptosis in human breast cancer, and whether

Clinical activity of cisplatin and prolo

Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study

✍ Fried, Getta; Stein, Moshe E.; Haim, Nissim 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 1 views

Background. This phase II study evaluates the antitumor activity and tolerance of cisplatin and prolonged oral administration of etoposide in metastatic breast cancer previously exposed to anthracyclines. Procedure. Twenty-seven patients with metastatic breast cancer who developed tumor progression

Tamoxifen-induced remission in breast ca

Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: A case report and review of the literature

✍ Andrea Manni; Baha'uddin M. Arafah 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 2 views

Estrogen receptor (ER) and progesterone

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

✍ Richard M. Elledge; Stephanie Green; Reginald Pugh; D. Craig Allred; Gary M. Cla 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 133 KB 👁 2 views

Results of estrogen receptor (ER) and progesterone receptor (PgR) ligand-binding assays (LBAs) are strongly correlated with ER and PgR by immuno-histochemistry (IHC). To investigate whether ER and PgR by IHC are also strongly correlated with tamoxifen response, time to treatment failure (TTF) and ov